Erlotinib Associated Trichomegaly in a Patient with Chronic Latanoprost Use
Journal Title: Journal of Hematology and Oncology Research - Year 2015, Vol 1, Issue 4
Abstract
Trichomegaly is a known adverse effect with the epidermal growth factor receptor inhibitor (EGFRI) and prostaglandin analogue drug classes. We present a chronic Latanoprost user who developed symptomatic trichomegaly subsequent to initiating an EGFRI medication and believe this case offers evidence that the two classes of medications may cause a similar eyelash manifestation through different mechanisms.
Authors and Affiliations
Burris CK, Richards NQ, Cowan CL Jr
Keywords
Related Articles
- EP ID EP249482
- DOI 10.14302/issn.2372-6601.jhor-15-667
- Views 220
- Downloads 0
Investigating the Relationship Between Children, Depression, and Pain in Black Women with Sickle Cell Disease (SCD)
Medical advances in obstetrics and hematology have encouraged researchers to investigate the reproductive risk in women with Sickle Cell Disease (SCD) attempting motherhood. However, few hematological studies have been...
Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with a Nodular Lymphocyte-Predominant Hodgkin Lymphoma. A Case Report and Review of Literature
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a known side effect of several oncology drugs, but it is rarely seen secondary to vinblastine with only a few cases reported worldwide. Herein we presen...
Itraconazole Prophylaxis for an Outbreak of Invasive Aspergillosis in a Hematology Ward after Hospital Construction Work
Objective: Hospital construction work, among other environmental factors, is a risk factor for invasive aspergillosis (IA). Methods: We retrospectively surveyed the incidence of IA in hematology-oncology patients befo...
Immune Thrombocytopenia after Allogeneic Stem Cell Transplantation: Case Report and Brief Overview of Treatment Strategies
Immune thrombocytopenia (ITP) is a rare but well-recognized post-allogeneic hematopoietic stem cell transplant (HSCT) autoimmune complication for which a standard treatment approach is lacking. Herein we report on an adu...
Successful Allogeneic Hematopoietic Stem Cell Transplantation from A 5/10 Mismatched Unrelated Donor in A Patient with Donor-Specific Anti-HLA Antibodies.
Hematopoietic stem cell transplantation (HSCT) from a mismatched unrelated donor, an haploidentical donor or a cord blood unit (CBU) has become a widely aviable approach if patient lacks a matched related or unrelated do...